Breaking News Instant updates and real-time market news.

UA

Under Armour

$17.75

0.08 (0.45%)

, UAA

Under Armour

$19.26

0.16 (0.84%)

13:59
09/18/18
09/18
13:59
09/18/18
13:59

NPD data shows Under Armour footwear sales down over 25% in August

Matt Powell, the Senior Industry Advisor, Sports at The NPD Group, stated in a LinkedIn post that "As expected, August was a disappointing month for sport footwear. Sales were down low singles in dollars and in units, yielding a flat performance in average selling price." Powell noted that Nike (NKE) brand sales grew in the very low singles on strong lifestyle results, Adidas (ADDYY) sales grew "only in the low singles digits," Skechers (SKX) athletic improved "in the low singles" and Under Armour footwear "declined more than 25%" last month. Reference Link

UA

Under Armour

$17.75

0.08 (0.45%)

UAA

Under Armour

$19.26

0.16 (0.84%)

NKE

Nike

$85.10

1.85 (2.22%)

ADDYY

Adidas

$0.00

(0.00%)

SKX

Skechers

$27.88

0.37 (1.35%)

  • 19

    Sep

  • 20

    Sep

  • 25

    Sep

  • 27

    Nov

UA Under Armour
$17.75

0.08 (0.45%)

08/29/18
BARD
08/29/18
NO CHANGE
Target $27
BARD
Outperform
Under Armour selloff on Dick's 'head fake' a buying opportunity, says Baird
Baird analyst Jonathan Komp noted that while Dick's Sporting Goods (DKS) reported its own "disappointing" earnings, the company called out continued sales challenges for Under Armour (UAA), which it attributed to expanded distribution. He believes current sporting goods disruption for Under Armour is already reflected in the company's 2018 earnings guidance and also believes other mid-tier channels have continued to show strong sales performance, pointing out that Kohl's (KSS) saw Under Armour accelerate in Q2. Komp, who views the selloff on Dick's comments a "compelling buying opportunity," keeps an Outperform rating and $27 price target on Under Armour Class A shares.
08/16/18
08/16/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ARGUS SAYS BUY LULULEMON: Argus analyst John Staszak upgraded Lululemon (LULU) to Buy from Hold with a price target of $150, citing the company's Q1 earnings beat and expectations of improved comps in Q2, along with its "substantial" growth opportunities to expand its brand overseas and particularly in China. Staszak contends that Lululemon's growth prospects are "among the best in the apparel sector," with a transition to higher margin e-commerce sales seen expanding its operating margins in the coming several years. The analyst further notes that his implied price target valuation multiple of 44-times forward earnings is within the multiple range of companies like Nike (NKE), Under Armour (UA), and VF Corp. (VFC) and justified by its rapid e-commerce adoption and strong overall growth. KIMBERLY-CLARK RAISED AFTER PRICE HIKES: JPMorgan analyst Andrea Teixeira upgraded shares of Kimberly-Clark (KMB) to Neutral from Underweight and raised her price target to $114 from $90 following yesterday's announcement that the company will increase prices or reduce package counts on key products in North America. The analyst notes that while it remains to be seen if the price increases will "actually hold" given the intensely competitive U.S. market, she believes investors will give Kimberly-Clark shares the benefit of the doubt. Additionally, she tells investors that Procter & Gamble's (PG) commentary that it plans to raise prices on some of its premium paper products and diapers is "supportive" of Kimberly-Clark's ability to pass on higher prices. COTY CUT TWO NOTCHES AT MERRILL: BofA Merrill Lynch analyst Olivia Tong double downgraded Coty to Underperform from Buy and cut its price target to $10 from $16. Tong said Coty is now more exposed to the mass beauty market following its merger with 41 brands from PG Beauty and is seeing disruption from smaller, niche brands and newer distribution channels. ACTIVISION PULLBACK SEEN AS OPPORTUNITY: Jefferies analyst Timothy O'Shea said he views China having frozen mobile game approvals as a temporary problem and "mostly a non-issue" as only the monetization approval process has been frozen, not the content approval process, and he notes administrators are already implementing a fast-track approval process to alleviate the problem. Activision Blizzard (ATVI) has a pipeline of new mobile games coming that he would still expect to launch in China over time and O'Shea sees the 15% pullback in the game maker's shares in the last month as a buying opportunity, he tells investors. He maintains a Buy rating and $90 price target on Activision shares.
08/16/18
ARGS
08/16/18
UPGRADE
Target $150
ARGS
Buy
Lululemon upgraded to Buy at Argus on international growth opportunity
As reported earlier, Argus analyst John Staszak upgraded Lululemon (LULU) to Buy from Hold with a price target of $150 while also raising his FY19 EPS outlook to $3.40 from $3.21. The analyst cites the company's Q1 earnings beat and expectations of improved comps in Q2, along with its "substantial" growth opportunities to expand its brand overseas and particularly in China. Staszak contends that Lululemon's growth prospects are "among the best in the apparel sector", with transition to higher margin e-commerce sales expanding its operating margins in the coming several years. The analyst further notes that his implied price target valuation multiple of 44-times forward earnings is within the multiple range of companies like Nike (NKE), Under Armour (UA), and VF Corp (VFC) and justified by its rapid e-commerce adoption and strong overall growth.
08/07/18
BARD
08/07/18
NO CHANGE
Target $27
BARD
Outperform
Under Armour designated as Fresh Pick at Baird
Baird analyst Jonathan Komp designated Under Armour shares as a Fresh Pick citing its recent pullback and stabilizing fundamentals, both which he sees supporting a good second half setup. Komp reiterated his Outperform rating and $27 price target on Under Armour shares.
UAA Under Armour
$19.26

0.16 (0.84%)

08/01/18
MSCO
08/01/18
INITIATION
Target $20
MSCO
Equal Weight
Under Armour initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Lauren Cassel initiated Under Armour with an Equal Weight and $20 price target citing rich valuation.
NKE Nike
$85.10

1.85 (2.22%)

09/18/18
ADAM
09/18/18
NO CHANGE
Target $95
ADAM
Buy
Survey shows overwhelming support for Nike's Kapernick ad, says Canaccord
Canaccord analyst Camilo Lyon conducted a proprietary survey to assess the impact of Nike's "Just Do It" ad featuring former NFL quarterback Colin Kapernick. The findings suggest the impact was overall positive and he expects the company to confirm that when it reports Q1 results next week. He believes the ad has had the intended effect of positively skewing the company's brand perception and likely provided a bump in sales. Lyon reiterated his Buy rating and $95 price target on Nike shares.
09/18/18
NEED
09/18/18
NO CHANGE
NEED
Hold
Nike positioned for 'solid' Q1, says Needham
Needham analyst Rick Patel is keeping his Hold rating on Nike ahead of its Q1 earnings next week based on its "premium valuation", even though he expects the company to post "solid results". The analyst cites his proprietary domestic checks suggesting "sequential improvement in promos and average selling prices". Patel also points to a favorable Q2 read-through from other athletic apparel names in the quarter, along with the "lean" inventory of Nike's wholesale customers. The analyst further anticipates outperformance in Nike's international segment based on its "strong brand and product momentum".
09/18/18
09/18/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN CUTS ESTIMATES, PRICE TARGET ON FACEBOOK: JPMorgan analyst Doug Anmuth lowered his 2019 and 2020 earnings estimates for Facebook (FB) by 5%-6% on the company's bigger investment increases over the next couple years, which he does not believe are fully captured in consensus estimates. Even with Facebook suggesting it could reach mid-30% operating margins in a few or several years, investments in 2019 could be larger than anticipated in consensus estimates, Anmuth said. The analyst also cut his price target for the shares to $195 from $205. However, he kept an Overweight rating on Facebook. PIVOTAL CUTS DISCOVERY TO SELL: Pivotal Research analyst Brian Wieser downgraded Discovery (DISCA) to Sell with an unchanged price target of $26. Despite "tepid" earnings and "underwhelming" longer-term trends, the stock is up 20% over the past month, Wieser noted. While Discovery's agreements with Hulu and Sling are positive, they do not meaningfully alter the company's fundamentals, the analyst added. His price target implies 19% downside from current share levels. MIZUHO BOOSTS AMD PRICE TARGET: Mizuho analyst Vijay Rakesh raised his price target for AMD (AMD) to $36 from $20 after meeting PC supply chain companies in Asia. AMD's expected server EPYC shipment spike in Q4 will be key, as Intel (INTC) continues to lack a CEO and a competitive technology response to AMD's 12nm Ryzen and 7nm Vega launch, Rakesh said. The analyst, who admits there could be "near-term bumps," kept a Buy rating on shares of AMD. CANACCORD SAYS KAPERNICK AD HAS 'OVERWHELMING' SUPPORT: Canaccord analyst Camilo Lyon conducted a proprietary survey to assess the impact of Nike's (NKE) "Just Do It" ad featuring former NFL quarterback Colin Kapernick. The findings suggest the impact was overall positive and he expects the company to confirm that when it reports Q1 results next week. He believes the ad has had the intended effect of positively skewing the company's brand perception and likely provided a bump in sales. Lyon reiterated his Buy rating and $95 price target on Nike shares. PIPER, WILLIAM BLAIR DEFEND NUTANIX: Nutanix (NTNX) shares dropped 11.5% Monday due to an article from The Information citing a potential competitive hyperconverged infrastructure offering from Google (GOOG, GOOGL), but Piper Jaffray analyst Andrew Nowinski views the selling pressure as "excessive" and reiterates an Overweight rating on Nutanix with a $66 price target. William Blair analyst Jason Ader called the fear of competition from Google "overblown" and reiterated an Outperform rating on Nutanix.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $93
PIPR
Overweight
Piper remains positive on Nike shares ahead of Q1 results
Piper Jaffray analyst Erinn Murphy remains positive on shares of Nike ahead of the company's fiscal Q1 results on September 25. The analyst sees upside to her Q1 sales and gross margin estimates, driven by "solid" domestic demand, strength in China and "on-going traction" in Europe. While currencies have been more volatile, upside on a constant currency basis and a strengthening fundamental backdrop should still support earnings and the stock moving higher over the near- to medium-term, Murphy tells investors in a pre-earnings research note. Further, the analyst's checks indicate Nike outperformed peer promotional levels and inventory management during back-to-school. She keeps an Overweight rating on the shares with a $93 price target.
ADDYY Adidas
$0.00

(0.00%)

08/23/18
STFL
08/23/18
NO CHANGE
Target $90
STFL
Buy
Nike brand styles 'popular' in retail checks for back-to-school, says Stifel
Stifel analyst Jim Duffy said his firm's annual back-to-school athletic footwear survey is showing Nike (NKE) brand styles referenced as the most popular choice in 67% of retail checks. While Nike's popularity was "stable" y/y, Duffy says his checks show breadth of strength across styles, a favorable mix to higher ASP styles, momentum from new offerings, and tight inventories with key channel partners. Further, the analyst says checks show a "lack of newness' from rival adidas (ADDYY) and lost momentum while Vans and other brand references increased. Ahead of Nike's Q1 earnings in September, Duffy maintains a Buy rating and $90 price target, adding that he has increased confidence in Nike's North America fundamentals and margins.
08/10/18
MSCO
08/10/18
NO CHANGE
MSCO
Overweight
North American deceleration for Adidas a positive for Nike, says Morgan Stanley
Morgan Stanley analyst Lauren Cassel noted that Adidas (ADDYY), which is covered by Ed Aubin and Elena Mariani, reported North American revenue growth that was strong on an absolute basis but showed some deceleration on a 1- and 2-year basis. While she expects Adidas' North American revenue growth to continue to outpace Nike (NKE), she said the top-line deceleration is a positive for Nike. Cassel keeps an Overweight rating on Nike while noting that her peers at the firm maintain an Equal Weight rating on Adidas.
07/19/18
JEFF
07/19/18
NO CHANGE
JEFF
Buy
Jefferies says Under Armour discounts down four straight months, buy shares
Jefferies analyst Randal Konik says July webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the fourth month in a row, while Adidas's (ADDYY) is up five months in a row. The analyst's visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR and Curry 5 sneakers are sold out in many sizes/colors, indicating "strong sell-through." Further, Nike (NKE) continues to regain share from Adidas in running across the U.S., with strength in Air VaporMax and Air Max 270, Konik tells investors in a research note titled "SNEAKER WARS: UAA HOVRing Above The Rest. Buy This Stock." He believes the data are encouraging and reinforce his belief in the upside potential for Under Armour shares.
07/17/18
WELS
07/17/18
DOWNGRADE
WELS
Market Perform
Adidas downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Tom Nikic downgraded Adidas (ADDYY) to Market Perform as he believes the tides have shifted in the athletic sector, which will slow the company's top- and bottom-line growth and limit upside potential to the shares. The analyst has become more cautious on the stock as Adidas is facing a two-pronged attack from their competitors globally, with Nike (NKE) gaining steam on the higher end of the sneaker market and Vans currently the "hot brand" in the $60-$100 price range. While Adidas has introduced new platforms to try to offset the maturing styles, results for silhouettes such as Prophere, Deerupt, Arkyn and Continental have been mixed, he contends, adding that the company's surprisingly-rapid deceleration in Western Europe presents risk to the North American market share thesis, as Europe has been a leading indicator for the brand over the years. Nikic sees near-term risk to estimates, as he thinks Q2 consensus EPS does not adequately account for the marketing investment around the World Cup, plus there's the fact that a Nike-sponsored team won the World Cup and the company will be lapping pre-World Cup sell-in beginning in Q4.
SKX Skechers
$27.88

0.37 (1.35%)

07/26/18
ARGS
07/26/18
DOWNGRADE
ARGS
Hold
Skechers downgraded to Hold at Argus after disappointing Q2 and Q3 view
As reported earlier, Argus analyst John Staszak downgraded Skechers to Hold from Buy, citing the company's Q2 earnings miss, as well as its reduced revenue growth outlook and "only a marginal" gross margin expansion in Q3. The analyst anticipates the company's increased investment in direct-to-consumer and international business to weigh on the operating margins over the next few quarters, even as the demand for its products is still seen as "solid'.
07/26/18
07/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Outperform from Strong Buy at Raymond James and to Neutral from Buy at Nomura Instinet and UBS. 2. e.l.f. Beauty (ELF) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying the bull case is more uncertain from here. 3. 3D Systems (DDD) downgraded to Underweight from Neutral at Piper Jaffray with analyst Troy Jensen saying a survey of resellers found that system demand downticked sequentially for 3D Systems with more below plan responses versus above plan. 4. Owens Corning (OC) downgraded to Neutral from Buy at BofA/Merrill with analyst John Lovallo citing disappointing Q2 results. 5. Skechers (SKX) downgraded to Hold from Buy at Argus with analyst John Staszak citing the company's Q2 earnings miss, as well as its reduced revenue growth outlook, and "only a marginal" gross margin expansion in Q3. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/18
MSCO
08/01/18
INITIATION
Target $28
MSCO
Equal Weight
Skechers initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Lauren Cassel initiated Skechers with an Equal Weight and $28 price target saying she is bullish on long-term topline gorwht, but cautious on margins and profitability. Cassel recommends staying on the sidelines until there consistent execution and operating income growth.
07/26/18
ARGS
07/26/18
DOWNGRADE
ARGS
Hold
Skechers downgraded to Hold from Buy at Argus

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.